Changeflow GovPing Healthcare & Life Sciences Max Slim Alpha-GPC + Citicoline Supplement Reca...
Urgent Enforcement Amended Final

Max Slim Alpha-GPC + Citicoline Supplement Recalled for Undeclared Caffeine

Favicon for recalls-rappels.canada.ca Health Canada Recalls & Safety Alerts
Filed
Detected
Email

Summary

Health Canada has issued a Type II national recall for Max Slim Alpha-GPC + Citicoline capsules (NPN 80129088), lot G9P12C24, manufactured by Maximum Slim of Pembroke Pines, Florida. The affected lot contains undeclared caffeine, creating a potential health risk for consumers who may be unaware of caffeine intake. The recall reaches the retail level, and consumers in possession of this product are advised to verify lot numbers and consult healthcare providers.

Published by HC on recalls-rappels.canada.ca . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

Health Canada has issued a Type II health product recall for Max Slim Alpha-GPC + Citicoline capsules (lot G9P12C24) distributed nationally in Canada. The recall was triggered after the affected lot was found to contain undeclared caffeine, which may pose health risks to consumers who are unaware of their caffeine consumption.

Healthcare providers and retailers should immediately identify any stock matching lot G9P12C24 and remove it from sale. Consumers who have purchased this product should verify their lot number, consult a healthcare provider before discontinuing use, and report any adverse health reactions to Health Canada.

What to do next

  1. Verify if your product is affected.
  2. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
  3. Contact the recalling firm if you have any questions about the recall.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Health product recall

Max Slim Alpha-GPC + Citicoline: The affected lot contains an undeclared ingredient (caffeine)

Brand(s)

Max Slim Alpha-GPC + Citicoline

Last updated

2026-04-20

Summary

Product Max Slim Alpha-GPC + Citicoline Issue Health products - Product quality What to do Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.

Distribution National

Affected products

Product Name Market Authorization Dosage Form Strength Lot number
Max Slim Alpha-GPC + Citicoline NPN 80129088 Capsule Cytidine 5'-(trihydrogen diphosphate) P'-[2-(trimethylammonio)ethyl] ester inner salt 400mg
L-alpha-Glycerophosphorylcholine 400mg G9P12C24

Issue

The affected lot contains an undeclared ingredient (caffeine).

What you should do

  1. Verify if your product is affected.
  2. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
  3. Contact the recalling firm if you have any questions about the recall.
  4. Report any health product related side effects to Health Canada.
  5. Report any other health product safety complaints to Health Canada.

Additional information

Background

Depth of Recall: Retailers

Details

Original published date:

2026-04-20

Alert / recall type Health product recall Category Health products - Natural health products Companies Maximum Slim

2114 N. Flamingo Rd #202

Pembroke Pines, FL

33028, USA

Published by Health Canada Audience General public Healthcare Industry Distribution National Recall class Type II Recall date

2026-04-13

Identification number RA-81910

Get notified

Receive emails about new and updated recall and safety alerts.

Subscribe

Report a health or safety concern

Get daily alerts for Health Canada Recalls & Safety Alerts

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from HC.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
HC
Filed
April 20th, 2026
Instrument
Enforcement
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Product recall response Market withdrawal
Geographic scope
Canada CA

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Product Safety Public Health

Get alerts for this source

We'll email you when Health Canada Recalls & Safety Alerts publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!